Key result
The PolarX Cryoballoon showed comparable efficacy to the AFA Cryoballoon for atrial fibrillation ablation, with time to reach -40°C predicting initial pulmonary vein isolation (OR 1.88; P<0.001).
Why the study?
The novel PolarX Cryoballoon required evaluation against the Arctic Front Advance (AFA) and identification of cryoablation metrics predictive of successful PVI.
Does the PolarX Cryoballoon have comparable efficacy and safety to the AFA Cryoballoon, and what metrics predict successful pulmonary vein isolation in patients with atrial fibrillation?
Population
Seventy patients undergoing cryoablation for AF
Comparison
PolarX Cryoballoon vs propensity-matched Arctic Front Advance cohort
Design
Prospective multi-centre study
Authors
Loading...
Comparable efficacy observed with PolarX versus AFA cryoballoon in this cohort; hypothesis-generating for temperature metrics pending randomized trials.
Cohort (n=70)
Yes
Does the PolarX Cryoballoon have comparable efficacy and safety to the AFA Cryoballoon, and what metrics predict successful pulmonary vein isolation in patients with atrial fibrillation?
Odds Ratio: 1.88
p-value: p=<0.001
The PolarX Cryoballoon demonstrates comparable acute efficacy and safety to the AFA Cryoballoon, with specific procedural metrics (temperature at 30s, nadir temperature, and time to isolation) predicting sustained pulmonary vein isolation.
Honarbakhsh et al. (2022) conducted a cohort in atrial fibrillation (AF) (n=70). PolarX Cryoballoon vs. Arctic Front Advance (AFA) Cryoballoon was evaluated on Initial pulmonary vein isolation (PVI) (OR 1.88, p=<0.001). The PolarX Cryoballoon showed comparable efficacy to the AFA Cryoballoon for atrial fibrillation ablation, with time to reach -40°C predicting initial pulmonary vein isolation (OR 1.88; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: